<DOC>
	<DOCNO>NCT00094003</DOCNO>
	<brief_summary>This study investigate safety NS-9 see well tolerated patient cancer metastasize ( spread ) liver another primary tumor . NS-9 drug develop go liver cause cell death specifically tumor cell . This study also set determine best dose use .</brief_summary>
	<brief_title>Study NS-9 Patients With Liver Metastases</brief_title>
	<detailed_description>This study require subject undergo 2 treatment cycle NS-9 . Each cycle consist daily , 1-hour I.V . infusion drug 5 day follow 23-day rest period . During rest period , subject see clinic weekly evaluation . Subjects favorable stable result 2 cycle may continue receive NS-9 extension phase study disease progress get side effect prevents continue therapy . After two cycle , appropriate , liver tumor measure radiologic image compare pre-treatment size .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>Male female least 18 year age . Patients liver metastasis various primary cancer curative treatment option exist . At least one measurable lesion ( CT MRI ) Life expectancy &gt; 3 month Childbearing potential woman must negative serum pregnancy test ECOG performance status : 01 Fully recover previous cancer therapy infection ( least 4 week radiation chemotherapy , least 3 week major surgical procedure least 2 week exploration/biopsy ) Discontinued investigational drug least 30 day Serum calcium &lt; 11 mg/dL Absolute neutrophil count ( ANC ) ≥1,500/mm3 , without growth factor support Hemoglobin ≥9.0 g/dL Platelet count ≥100,000/mm3 Serum creatinine ≤1.5 time upper limit normal ( ULN ) Bilirubin ≤1.5 time ULN ALT AST ≤3 time ULN Amylase lipase ≤ ULN PT PTT &lt; 1.5 time ULN ECG acute abnormality Afebrile ( ≤37.5C 99.5F ) Willingness ability comply study requirement Subject mentally legally incapacitate , significant emotional psychiatric problem . Concomitant primary malignant and/or nonmalignant liver disease ( primary liver cancer , acute chronic hepatitis , cirrhosis , alcoholic liver disease ) . History pancreatic disease ( e.g. , pancreatitis , pancreatic malignancy ) . New York Heart Association classification Class III IV Uncontrolled intercurrent illness include limited : hypertension , seizure disorder , renal , gastrointestinal , hematological disease . Clinically relevant systemic disease ( malignancy malignancyrelated hepatic dysfunction ) make implementation protocol interpretation study result difficult . Pregnant nursing , unwilling agree use effective reliable contraceptive measure . Subject receive radiation &gt; 25 % total bone marrow . Subject history illness would preclude study participation . Subject brain metastasis . Subject allergy egg yolk . Subject receive lowmolecular weight heparin treatment blood coagulation disorder ( e.g. , deep vein thrombosis , pulmonary embolism ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Liver metastasis</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Esophagus cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Skin cancer</keyword>
	<keyword>Renal Cancer</keyword>
	<keyword>Liver metastasis</keyword>
</DOC>